Award
National Cancer Institute RFA-CA-23-028
Developing ribosome biogenesis inhibitors for the prevention of cancer
Recipient
University of Texas Southwestern Medical Center
Award Amount
$292,886.00
Ceiling
$292,886.00
Awarded
May 14, 2026
Identifier
RFA-CA-23-028
NIH awarded a grant to develop ribosome biogenesis inhibitors to prevent cancer, with a budget of about $293,000 for one year starting May 2026. The research includes platform optimization, natural product screening, and mouse model testing.
Description
This NIH grant supports research on developing inhibitors of ribosome biogenesis to prevent liver cancer. The project involves optimizing platforms, screening natural product libraries, and testing in mouse models. The award is for a one-year period starting May 2026, with a total budget of approximately $293,000. The principal investigator is Professor Michael Buszczak at the University of Texas Southwestern Medical Center in Dallas.